SAL056 bone-strengthening treatment for postmenopausal osteoporosis
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 45 and 80 years old
- You reached natural menopause at least 3 years ago, or had surgical menopause at least 3 years ago (surgery after age 40)
- You have a diagnosed case of osteoporosis (weak bones)
- Your weight is healthy for your height (BMI between 18–30)
- You can independently travel to the hospital for injections
- You have not taken teriparatide (a bone-strengthening injection) in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily injection called abaloparatide, which helps strengthen bones and reduce the chance of breaking a bone. It is for postmenopausal women with osteoporosis who are at higher risk of fractures.
This study looks at ways to prevent and treat “brittle bone” refractures after a recent fracture in people with osteoporosis. If you’ve had a new hip, spine, or other bone fracture, the trial may test strategies to lower the chance of another fracture.
This study tests an investigational injection called TST002 to see if it can help strengthen bones in postmenopausal women with osteoporosis or low bone mass. It may help reduce the risk of fractures.
This study tests two injectable medications (romosozumab and abaloparatide) that help strengthen bones in women after menopause. Researchers will also look at blood markers to understand why some women respond better to treatment than others.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
Hear when a new Postmenopausal Women With Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.